Bao 2021 Cells: Difference between revisions
(Created page with "{{Publication |title=Bao MH, Wong CC (2021) Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10:1715. doi: 10.3390/cells10071715 |info=[https://pub...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Bao MH, Wong CC (2021) Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10:1715. doi | |title=Bao MH, Wong CC (2021) Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10:1715. https://doi.org/10.3390/cells10071715 | ||
|info=[https://pubmed.ncbi.nlm.nih.gov/34359884/ PMID: 34359884 Open Access] | |info=[https://pubmed.ncbi.nlm.nih.gov/34359884/ PMID: 34359884 Open Access] | ||
|authors=Bao MH, Wong CC | |authors=Bao MH, Wong CC | ||
| Line 8: | Line 8: | ||
|editor=Gnaiger E | |editor=Gnaiger E | ||
}} | }} | ||
[[File:Bao 2021 Cells CORRECTION.png|right|400px]] | |||
{{Template:Correction FADH2 and S-pathway}} | |||
{{Labeling | {{Labeling | ||
|enzymes=Complex II;succinate dehydrogenase | |enzymes=Complex II;succinate dehydrogenase | ||
}} | }} | ||
Latest revision as of 23:08, 23 April 2023
| Bao MH, Wong CC (2021) Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10:1715. https://doi.org/10.3390/cells10071715 |
Abstract: Hypoxia, low oxygen (O2) level, is a hallmark of solid cancers, especially hepatocellular carcinoma (HCC), one of the most common and fatal cancers worldwide. Hypoxia contributes to drug resistance in cancer through various molecular mechanisms. In this review, we particularly focus on the roles of hypoxia-inducible factor (HIF)-mediated metabolic reprogramming in drug resistance in HCC. Combination therapies targeting hypoxia-induced metabolic enzymes to overcome drug resistance will also be summarized. Acquisition of drug resistance is the major cause of unsatisfactory clinical outcomes of existing HCC treatments. Extra efforts to identify novel mechanisms to combat refractory hypoxic HCC are warranted for the development of more effective treatment regimens for HCC patients.
• Bioblast editor: Gnaiger E
Correction: FADH2 and Complex II
- FADH2 is shown as the substrate feeding electrons into Complex II (CII). This is wrong and requires correction - for details see Gnaiger (2024).
- Gnaiger E (2024) Complex II ambiguities ― FADH2 in the electron transfer system. J Biol Chem 300:105470. https://doi.org/10.1016/j.jbc.2023.105470 - »Bioblast link«
Labels:
Enzyme: Complex II;succinate dehydrogenase
